Hosted by Leiden University Medical Center, the EU MSC2 2017 meeting in Leiden, NL on September 12th and 13th will assemble twelve EU-funded, mesenchymal stromal cell-focussed consortia. Projects to be presented include: REDDSTAR, REACH, RETHRIM, Stellar, MERLIN, Nephstrom, SCIENCE, VISICORT and Adipoa-2, AUTOSTEM, BOOSTB4, SEPCELL, RESSTORE, and RESPINE. This two day, interactive meeting will be held at the Stadsgehoorzaal Leiden. Three overarching aspects of the EU-MSC2 meeting include: mechanisms of action and potency assays; an interactive panel discussion on product development, and product development and market authorisation in a changing regulatory landscape.

The objectives of the meeting are to:

Enhance knowledge-sharing between EU research groups working in the mesenchymal stromal cell biology domain

Engage with European Commission Project Officers and other stakeholders from International Society of Cellular Therapy, stem cell ethicists and the European Medicines Agency (EMA)

Assemble trans-disciplinary research groups working across the global health spectrum but with a common focus of mesenchymal stromal cell biology

Bring up-and-coming researchers together for networking purposes, and to explore future consortium building and international funding application opportunities

Share this entry

http://fp7merlin.eu/wp-content/uploads/2017/08/EU-MSC2-logo-1.jpg213272merlin_adminhttp://fp7merlin.eu/wp-content/uploads/2016/01/main_logo-300x60.pngmerlin_admin2017-08-03 15:45:542017-08-03 16:04:15MERLIN will present at EU-MSC2 meeting in Leiden in September

Project Information

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602363. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.